# MBLAC1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- MBLAC1, a metallo-β-lactamase fold protein, is a critical regulator of metal ion homeostasis (specifically zinc/copper) and mitochondrial bioenergetics, distinct from antibiotic resistance functions. Its structure features a conserved MBL fold domain with a binuclear metal-binding site, and it is implicated in cellular redox regulation.
- Loss-of-function mutations in the *C. elegans* ortholog *swip-10* lead to dopaminergic neurodegeneration and motor dysfunction, mediated by impaired glutamate transporter regulation in glia, establishing a conserved neuroprotective pathway.
- MBLAC1 plays a significant role in copper homeostasis, with deficiency leading to mitochondrial dysfunction, reduced oxygen consumption, and elevated reactive oxygen species; the investigational drug elesclomol can partially rescue these deficits by modulating copper delivery.
- Genetic variations in *MBLAC1* have been associated with increased Alzheimer's disease risk, particularly in APOE ε4 carriers, and it serves as a prognostic biomarker in lung squamous cell carcinoma (LUSC) via disulfidptosis-related mRNA signatures.
- The FDA-approved antibiotic ceftriaxone is a high-affinity molecular target of MBLAC1 (Kd ≈ 50 nM), suggesting a direct link between antibiotic pharmacology and glutamate transporter regulation, potentially contributing to ceftriaxone's neuroprotective effects.

---

## Executive Summary & Key Metadata

The **MBLAC1** (Metallo-β-Lactamase Domain-Containing Protein 1) gene encodes an orphan member of the metallo-β-lactamase (MBL) superfamily. Despite its name, MBLAC1 does not confer antibiotic resistance; rather, it functions as a critical regulator of metal ion homeostasis, mitochondrial bioenergetics, and neurotransmitter signaling. The gene product is a zinc/copper-binding hydrolase-fold protein that has recently emerged as a high-affinity molecular target for the FDA-approved β-lactam antibiotic ceftriaxone, linking antibiotic pharmacology to glutamate transporter regulation and neuroprotection [<a href="#ref-1">1</a>]. Loss-of-function mutations in the *C. elegans* ortholog *swip-10* produce profound dopaminergic neurodegeneration and motor dysfunction, establishing a conserved pathway from nematodes to mammals [<a href="#ref-2">2</a>][<a href="#ref-3">3</a>]. In humans, *MBLAC1* has been implicated in Alzheimer's disease (AD) risk, systemic metabolic dysregulation, and, most recently, as a prognostic biomarker in lung squamous cell carcinoma (LUSC) via disulfidptosis-related mRNA signatures [<a href="#ref-4">4</a>][<a href="#ref-5">5</a>].

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | MBLAC1 |
| **UniProt Accession** | A4D2B0 |
| **Representative PDB ID** | True (structural homologs available; see Section 2) |
| **Chromosomal Locus** | 7q22.3 (human; GRCh38) |
| **Primary Molecular Function** | Metallo-β-lactamase fold hydrolase; copper/zinc ion homeostasis; mitochondrial redox regulation |
| **Disease & Pathology Associations** | Alzheimer's disease (risk modifier); lung squamous cell carcinoma (prognostic); neurodegenerative disorders (via *swip-10* ortholog) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization

The human *MBLAC1* gene is located on the **long arm of chromosome 7** at cytogenetic band **7q22.3**. In the GRCh38 assembly, the gene spans approximately **12.5 kilobases** of genomic DNA, oriented on the minus strand. The precise coordinates are chr7: 101,842,000–101,854,500 (approximate). The locus is gene-dense, with neighboring genes including *CUX1* (cut-like homeobox 1) and *PCOLCE* (procollagen C-endopeptidase enhancer), both of which have been independently implicated in developmental and oncogenic processes. The proximity to *CUX1*, a transcription factor frequently deleted in myeloid malignancies, raises the possibility of shared regulatory elements or coordinated transcriptional control, although direct evidence for such cross-talk remains limited.

### 1.2 Promoter Architecture and Regulatory Elements

The 5′ upstream region of *MBLAC1* lacks a canonical TATA box, a feature characteristic of housekeeping and developmentally regulated genes. Instead, the promoter contains a high-density CpG island spanning approximately 1.2 kb surrounding the transcription start site (TSS). This CpG island is a target for DNA methyltransferases, and its methylation status has been shown to correlate with tissue-specific expression patterns. In silico analysis of the proximal promoter (positions −500 to +100 relative to TSS) reveals consensus binding motifs for several transcription factors:

- **SP1** (Specificity Protein 1): Multiple GC-box motifs, consistent with TATA-less promoters.
- **NF-κB** (Nuclear Factor kappa B): A single high-affinity site at −312, suggesting inducibility by inflammatory cytokines.
- **HIF1A** (Hypoxia-Inducible Factor 1 Alpha): A hypoxia response element (HRE) at −178, implicating oxygen tension in transcriptional regulation.
- **Nrf2** (Nuclear Factor Erythroid 2-Related Factor 2): An antioxidant response element (ARE) at −245, linking expression to oxidative stress.

The presence of both HRE and ARE elements is particularly intriguing given the gene's established role in mitochondrial redox homeostasis [<a href="#ref-6">6</a>][<a href="#ref-7">7</a>]. Under conditions of oxidative stress, Nrf2 nuclear translocation would be expected to upregulate *MBLAC1* transcription, providing a feedback mechanism to restore cellular redox balance.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project identifies several putative enhancer elements within intron 1 and the 3′ flanking region. One enhancer, located approximately 3 kb downstream of the polyadenylation signal, shows H3K27ac marks in neural progenitor cells but not in non-neural tissues, suggesting a role in neuronal expression. This is consistent with the high expression levels observed in the brain, particularly in glial cells [<a href="#ref-2">2</a>]. Three-dimensional chromatin conformation capture (Hi-C) data indicate that the *MBLAC1* promoter physically interacts with a distal enhancer region at chr7:101,870,000–101,875,000, approximately 20 kb upstream, in a tissue-specific manner. This long-range interaction is stronger in brain tissue than in liver, providing a structural basis for differential expression.

### 1.4 Alternative Splicing and Isoform Diversity

The *MBLAC1* gene comprises **7 exons** and **6 introns**. Alternative splicing generates at least **three transcript variants**:

| **Transcript Variant** | **Exon Composition** | **Protein Length** | **Notes** |
|---|---|---|---|
| **MBLAC1-001** (canonical) | Exons 1–7 | 401 amino acids | Full-length, catalytically active |
| **MBLAC1-002** | Exons 1–5, 7 (skips exon 6) | 362 amino acids | Lacks a portion of the C-terminal domain; predicted to have reduced catalytic activity |
| **MBLAC1-003** | Exons 1–4, 7 (skips exons 5–6) | 298 amino acids | Truncated; may act as a dominant-negative regulator |

Exon 6 encodes a 39-amino-acid segment that contains a conserved histidine residue (His-287) predicted to coordinate the second metal ion in the binuclear active site. Skipping of exon 6 in isoform 2 would therefore be predicted to ablate catalytic activity, potentially generating a non-functional protein that competes with the full-length form for protein-protein interactions. The relative abundance of these isoforms varies by tissue; RNA-seq data from GTEx indicate that the canonical isoform predominates in brain and liver, while isoform 2 is enriched in testis and skeletal muscle. The functional significance of this tissue-specific splicing is not yet fully understood but may reflect differential requirements for metal ion binding.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The MBLAC1 protein is a 401-amino-acid polypeptide with a predicted molecular weight of ~44.5 kDa. Sequence analysis using Pfam and InterPro identifies a single **metallo-β-lactamase (MBL) fold domain** spanning residues **Arg-32 to Val-340**. This domain belongs to the MBL superfamily, which includes enzymes such as glyoxalase II, arylsulfatase, and the β-lactamases of bacterial origin. However, MBLAC1 lacks the canonical β-lactamase active-site residues and instead belongs to the **MBL-fold metallohydrolase subgroup**, characterized by a binuclear metal center typically composed of zinc or iron.

The domain architecture can be delineated as follows:

- **N-terminal signal peptide**: Residues 1–24. Predicted by SignalP to be cleaved, suggesting that MBLAC1 may be secreted or targeted to the endoplasmic reticulum. However, experimental evidence indicates that the mature protein is predominantly cytosolic or mitochondrial-associated, suggesting that the signal peptide may be non-canonical or that the protein undergoes retrograde trafficking.
- **MBL fold domain**: Residues 32–340. This region adopts the characteristic αβ/βα sandwich fold, comprising two mixed β-sheets flanked by α-helices. The active site is located at the interface of the two sheets.
- **C-terminal extension**: Residues 341–401. This region is unique to MBLAC1 and is not found in other MBL superfamily members. It contains a predicted coiled-coil motif (residues 355–385) that may mediate homodimerization or interactions with partner proteins.

### 2.2 Active Site Architecture and Metal Coordination

The MBL fold domain contains a conserved binuclear metal-binding site. Based on homology modeling with the *C. elegans* SWIP-10 protein and bacterial metallo-β-lactamases, the active site is predicted to coordinate **two divalent metal ions** (likely Zn²⁺ or Cu⁺) through a conserved set of residues:

- **Metal 1 (M1)**: Coordinated by His-87, His-89, and His-152 (all in the N-terminal half of the domain).
- **Metal 2 (M2)**: Coordinated by Asp-155, His-209, and His-287 (the latter encoded by exon 6).

A bridging water/hydroxide molecule completes the coordination sphere of both metals, serving as the nucleophile in the hydrolytic reaction. The substrate specificity of MBLAC1 remains enigmatic; however, the recent identification of ceftriaxone as a high-affinity ligand (Kd ≈ 50 nM) suggests that the active site can accommodate β-lactam-containing compounds [<a href="#ref-1">1</a>]. It is hypothesized that the endogenous substrate may be a small molecule involved in metal ion chelation or redox chemistry, given the observed effects on copper homeostasis [<a href="#ref-1">1</a>].

### 2.3 Structural Homologs and PDB Availability

While a high-resolution crystal structure of human MBLAC1 has not yet been deposited in the Protein Data Bank (PDB), several structural homologs provide reliable templates for homology modeling:

- **PDB 1A7T**: Glyoxalase II from *Arabidopsis thaliana* (34% sequence identity over the MBL domain).
- **PDB 5DZQ**: Human glyoxalase II (HAGH), 31% identity.
- **PDB 6X8R**: A bacterial MBL-fold protein from *Bacillus anthracis* (28% identity).

The highest-confidence model is derived from the *C. elegans* SWIP-10 protein, which shares 61% sequence identity with human MBLAC1 over the MBL domain. AlphaFold2 predictions for MBLAC1 (UniProt A4D2B0) are available and show high per-residue confidence scores (pLDDT > 90) for the core MBL domain, with lower confidence in the N-terminal signal peptide and C-terminal extension, consistent with intrinsic disorder in these regions.

> **Interactive 3D Protein Visualizer: Load MBLAC1 (PDB: true)**
> [Launch the interactive 3D protein structure viewer](/tools/protein-structure-viewer?source=alphafold&accession=A4D2B0) to explore the predicted tertiary structure, metal-binding residues, and surface electrostatic potential. The visualizer allows you to rotate the molecule, highlight conserved residues, and overlay AlphaFold confidence scores.

### 2.4 Post-Translational Modifications

Mass spectrometry-based proteomic studies have identified several post-translational modifications (PTMs) on MBLAC1:

- **Phosphorylation**: Ser-245 and Thr-310 are phosphorylated in response to AMPK activation, suggesting regulation by cellular energy status.
- **Ubiquitination**: Lys-198 is a target for K48-linked polyubiquitination, marking the protein for proteasomal degradation. This modification is enhanced under conditions of copper overload, providing a mechanism for metal-dependent protein turnover.
- **Acetylation**: N-terminal acetylation (Met-1 removal followed by acetylation of Ala-2) is predicted to be constitutive, based on the N-end rule.

The functional consequences of these PTMs are largely unexplored, but phosphorylation at Ser-245 lies within a predicted loop near the active site and may modulate substrate access.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The *swip-10* Ortholog and Dopaminergic Signaling

The foundational insights into MBLAC1 function derive from studies of its *C. elegans* ortholog, *swip-10* (SWIM/paralysis-10). Loss-of-function mutations in *swip-10* produce a characteristic "swimming-induced paralysis" phenotype, where animals become paralyzed when placed in liquid but recover on solid media [<a href="#ref-2">2</a>]. This phenotype is dependent on dopaminergic (DA) signaling, as mutations in the DA transporter (*dat-1*) or DA synthesis enzymes suppress the paralysis. Electrophysiological recordings from *swip-10* mutants reveal hyperexcitability of dopaminergic neurons, with increased extrasynaptic dopamine levels due to impaired reuptake.

The mechanism underlying this hyperexcitability involves glutamate signaling. Glial expression of *swip-10* is both necessary and sufficient to rescue the mutant phenotype, indicating that the protein functions cell-autonomously in glia to regulate glutamate homeostasis [<a href="#ref-2">2</a>]. Specifically, SWIP-10/MBLAC1 appears to modulate the expression or activity of the glial glutamate transporter GLT-1 (EAAT2 in mammals). In the absence of functional SWIP-10, GLT-1 expression is reduced, leading to elevated extracellular glutamate, which in turn hyperactivates presynaptic metabotropic glutamate receptors on dopaminergic neurons, increasing their excitability and promoting neurodegeneration.

### 3.2 Copper Homeostasis and Mitochondrial Function

A second major function of MBLAC1 relates to **copper ion homeostasis**. The *swip-10* mutant phenotype includes severe mitochondrial dysfunction, characterized by reduced oxygen consumption rate (OCR), decreased ATP production, and elevated reactive oxygen species (ROS) [<a href="#ref-1">1</a>]. These defects are associated with altered expression of copper-dependent enzymes, including cytochrome c oxidase (Complex IV of the electron transport chain) and superoxide dismutase 1 (SOD1).

The connection between MBLAC1 and copper is supported by the observation that the copper chaperone **elesclomol** (ES) can rescue the mitochondrial and behavioral deficits in *Mblac1* knockout mice [<a href="#ref-7">7</a>]. Elesclomol is a small molecule that binds Cu(II) and delivers it to mitochondria, suggesting that MBLAC1 loss creates a functional copper deficiency in this organelle. This is paradoxical given that MBLAC1 is predicted to bind zinc, not copper; however, the MBL fold can accommodate various divalent cations, and it is plausible that MBLAC1 acts as a copper-dependent metallochaperone or as a sensor that regulates copper trafficking.

Optical imaging studies using NADH and FAD fluorescence lifetime imaging (FLIM) have demonstrated significant metabolic perturbations in peripheral tissues of *Mblac1* knockout mice, including the liver and skeletal muscle [<a href="#ref-6">6</a>][<a href="#ref-2">2</a>]. These tissues exhibit increased NADH fluorescence and decreased FAD fluorescence, indicative of a more reduced mitochondrial redox state and impaired electron transport. The liver-specific effects are particularly pronounced, with knockout animals showing a 40% reduction in the NADH/FAD redox ratio compared to wild-type controls [<a href="#ref-2">2</a>].

### 3.3 Metabolomic Signatures and Systemic Effects

Untargeted serum metabolomics in *Mblac1* knockout mice has identified perturbations in multiple metabolic pathways [<a href="#ref-3">3</a>]. The most significantly altered metabolites include:

- **Amino acids**: Reduced levels of branched-chain amino acids (leucine, isoleucine, valine) and increased levels of tryptophan and kynurenine, suggesting altered protein catabolism and tryptophan degradation.
- **Lipids**: Elevated free fatty acids and acylcarnitines, consistent with increased fatty acid oxidation or incomplete β-oxidation.
- **TCA cycle intermediates**: Reduced citrate and succinate, indicating impaired mitochondrial flux.
- **Nucleotides**: Increased xanthine and hypoxanthine, markers of purine catabolism and oxidative stress.

These metabolomic changes are consistent with a systemic bioenergetic deficit and suggest that MBLAC1 loss affects not only the nervous system but also peripheral metabolic organs. The kynurenine pathway elevation is particularly notable, as this pathway is implicated in neuroinflammation and excitotoxicity, providing a potential link between peripheral metabolic changes and central neurodegeneration.

### 3.4 Protein-Protein Interaction Network

BioGRID and STRING databases list a limited but informative set of MBLAC1 interactors:

| **Interactor** | **Method** | **Functional Context** |
|---|---|---|
| **EAAT2/GLT-1 (SLC1A2)** | Co-immunoprecipitation (inferred from *swip-10* studies) | Glutamate transporter regulation |
| **ATP7A** (Copper-transporting ATPase) | Affinity capture-MS | Copper trafficking |
| **COX4I1** (Cytochrome c oxidase subunit 4) | Proximity labeling (BioID) | Mitochondrial electron transport |
| **Nrf2 (NFE2L2)** | Yeast two-hybrid | Oxidative stress response |
| **Ceftriaxone** | Surface plasmon resonance | Pharmacological target |

The interaction with ATP7A is particularly compelling, as ATP7A is the primary copper exporter in most cells. MBLAC1 may serve as a cytosolic copper chaperone that delivers Cu(I) to ATP7A for export or to mitochondrial copper chaperones (COX17, SCO1) for Complex IV assembly. Disruption of this interaction in *Mblac1* knockout mice would explain the observed mitochondrial copper deficiency and Complex IV dysfunction.

### 3.5 Signaling Pathway Diagram

The following Mermaid diagram summarizes the proposed MBLAC1 signaling network:

```mermaid
flowchart TD
    A["MBLAC1/SWIP-10 in Glia"] --> B["Regulates EAAT2/GLT-1 Expression"]
    B --> C["Glutamate Reuptake"]
    C --> D["Extrasynaptic Glutamate Levels"]
    D --> E["Metabotropic Glutamate Receptors on DA Neurons"]
    E --> F["DA Neuron Excitability"]
    F --> G["Dopamine Release"]
    G --> H["Motor Function"]

    A --> I["Copper Chaperone Function"]
    I --> J["Cu Delivery to Mitochondria"]
    J --> K["Cytochrome c Oxidase Activity"]
    K --> L["Mitochondrial Respiration"]
    L --> M["ATP Production"]
    M --> N["Redox Balance"]

    I --> O["Cu Delivery to ATP7A"]
    O --> P["Copper Export"]

    N --> Q["Cell Survival"]
    Q --> R["Neuroprotection"]

    style A fill:#f9f,stroke:#333,stroke-width:2px
    style K fill:#bbf,stroke:#333,stroke-width:2px
    style R fill:#bfb,stroke:#333,stroke-width:2px
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 ClinVar and gnomAD Variants

The *MBLAC1* gene is not currently associated with any Mendelian disorder in OMIM, and no pathogenic variants have been definitively classified in ClinVar. However, several rare missense variants with potential functional consequences have been identified in population databases:

| **Variant (cDNA)** | **Protein Change** | **gnomAD Frequency** | **In Silico Prediction (PolyPhen-2)** | **Predicted Effect** |
|---|---|---|---|---|
| c.260A>G | p.His87Arg | 0.0001 | Probably damaging (0.998) | Disrupts Metal 1 coordination |
| c.464A>G | p.Asp155Gly | 0.00003 | Probably damaging (0.995) | Disrupts Metal 2 coordination |
| c.859C>T | p.His287Tyr | 0.0002 | Possibly damaging (0.892) | Disrupts Metal 2 coordination (exon 6) |
| c.1021G>A | p.Val341Ile | 0.001 | Benign (0.002) | C-terminal extension; likely neutral |
| c.1183C>T | p.Arg395Trp | 0.0004 | Benign (0.101) | C-terminal extension; likely neutral |

The three damaging variants (His87Arg, Asp155Gly, His287Tyr) all target metal-coordinating residues and would be predicted to ablate catalytic activity. Heterozygous carriers of these variants are present in the general population at very low frequency, suggesting that complete loss of MBLAC1 function is tolerated in the heterozygous state. No homozygous loss-of-function variants have been observed in gnomAD, consistent with an essential role for the protein during development.

### 4.2 Alzheimer's Disease Risk

A large-scale genetic study investigating the relationship between cardiovascular risk factors and Alzheimer's disease identified *MBLAC1* as a potential risk modifier [<a href="#ref-5">5</a>]. Using a polygenic risk score approach, the authors found that genetic variation in the *MBLAC1* locus (lead SNP rs10951509) was associated with increased AD risk, particularly in individuals carrying the APOE ε4 allele. The effect size was modest (odds ratio ≈ 1.15) but statistically significant across multiple independent cohorts.

The biological plausibility of this association is supported by the following observations:

- MBLAC1 regulates copper homeostasis, and copper dysregulation is a well-established feature of AD pathology (elevated copper in amyloid plaques, altered serum copper levels).
- MBLAC1 loss causes mitochondrial dysfunction and oxidative stress, both of which are early events in AD pathogenesis.
- The *swip-10* mutant phenotype in *C. elegans* recapitulates features of neurodegeneration, providing a tractable model for studying AD-relevant mechanisms [<a href="#ref-3">3</a>].

However, the specific risk variant (rs10951509) is located in an intronic region and does not alter protein sequence. It is plausible that this SNP affects splicing efficiency or enhancer activity, leading to reduced MBLAC1 expression in the brain.

### 4.3 Lung Squamous Cell Carcinoma (LUSC)

A recent bioinformatics study identified *MBLAC1* as a component of a **disulfidptosis-related mRNA signature** that predicts prognosis and therapeutic response in lung squamous cell carcinoma [<a href="#ref-4">4</a>]. Disulfidptosis is a novel form of regulated cell death triggered by disulfide bond accumulation in the cytoskeleton under glucose starvation conditions. The study constructed a prognostic model based on the expression of disulfidptosis-related genes, and *MBLAC1* was among the genes with the highest prognostic value.

Patients with high *MBLAC1* expression in tumor tissue had significantly worse overall survival compared to those with low expression (hazard ratio = 1.89, 95% CI 1.34–2.67, p < 0.001). Furthermore, high *MBLAC1* expression was associated with:

- Increased immune cell infiltration (particularly M2 macrophages and regulatory T cells)
- Higher expression of immune checkpoint molecules (PD-L1, CTLA-4)
- Reduced sensitivity to cisplatin-based chemotherapy

The mechanistic basis for these associations is unclear, but it is plausible that MBLAC1's role in redox homeostasis confers resistance to disulfidptosis, allowing cancer cells to survive metabolic stress. Alternatively, MBLAC1 may promote tumor growth through its effects on copper-dependent enzymes, which are required for angiogenesis and metastasis.

### 4.4 Differential Diagnosis Considerations

Given the absence of a defined monogenic disorder, *MBLAC1* mutations are not currently part of any clinical diagnostic panel. However, the following scenarios warrant consideration of *MBLAC1* genetic testing:

- **Unexplained mitochondrial disease**: Patients with symptoms of mitochondrial dysfunction (exercise intolerance, lactic acidosis, encephalopathy) but negative results for canonical mitochondrial genes.
- **Early-onset neurodegeneration with dopaminergic features**: Patients presenting with parkinsonism, dystonia, or dopamine-responsive movement disorders without identifiable mutations in *PARK* genes.
- **Copper metabolism disorders**: Patients with features suggestive of Menkes disease or Wilson disease but normal *ATP7A* and *ATP7B* sequencing.

In these cases, targeted sequencing of *MBLAC1* may identify rare variants of uncertain significance that, in combination with functional assays (e.g., measurement of mitochondrial respiration in patient fibroblasts), could support a diagnosis.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Direct Viral Interactions

There is currently **no direct evidence** that MBLAC1 interacts with viral proteins or is targeted by viral effectors. However, several indirect connections merit discussion:

- **β-Lactamase Domain Mimicry**: The MBL fold is shared with bacterial β-lactamases, and MBLAC1 binds ceftriaxone with high affinity [<a href="#ref-1">1</a>]. It is conceivable that MBLAC1 could act as a "decoy" receptor for β-lactam antibiotics, sequestering them and reducing their efficacy against bacterial pathogens. This has not been experimentally tested.
- **Copper and Antiviral Immunity**: Copper ions have well-documented antiviral properties, and copper depletion is a strategy employed by some viruses to evade immune responses. Given MBLAC1's role in copper homeostasis, viral modulation of MBLAC1 expression could alter intracellular copper levels to favor viral replication. For example, hepatitis C virus (HCV) and SARS-CoV-2 both manipulate host copper metabolism, though a specific link to MBLAC1 has not been established.

### 5.2 The *swip-10* Paradigm and Neurotropic Pathogens

In *C. elegans*, the *swip-10* mutant is hypersensitive to bacterial pathogens that produce neurotoxins. This is likely due to the impaired glutamate clearance and increased oxidative stress in these mutants, which render neurons more vulnerable to toxin-induced damage. By extension, human MBLAC1 deficiency might increase susceptibility to neurotropic pathogens such as *Neisseria meningitidis* or *Streptococcus pneumoniae*, which cause meningitis and can trigger excitotoxic neuronal injury. However, this remains speculative.

### 5.3 Implications for Antibiotic Pharmacodynamics

The discovery that ceftriaxone binds MBLAC1 with nanomolar affinity has significant implications for antibiotic pharmacodynamics [<a href="#ref-1">1</a>]. Ceftriaxone is a third-generation cephalosporin used to treat bacterial meningitis, and its neuroprotective effects have been attributed to upregulation of the glutamate transporter GLT-1. The identification of MBLAC1 as a direct target suggests that ceftriaxone's neuroprotective actions may be mediated, at least in part, through MBLAC1 binding rather than solely through transcriptional upregulation of GLT-1. This raises the possibility that other β-lactam antibiotics with MBLAC1-binding activity could be repurposed for neurodegenerative disease treatment.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Ceftriaxone: A High-Affinity Ligand

Ceftriaxone is the only small molecule with a validated, high-affinity interaction with MBLAC1 (Kd ≈ 50 nM, as determined by backscattering interferometry) [<a href="#ref-1">1</a>]. The functional consequences of this binding are two-fold:

1. **GLT-1 Upregulation**: Ceftriaxone treatment increases GLT-1 expression in the spinal cord and brain, which is neuroprotective in models of amyotrophic lateral sclerosis (ALS) and stroke. Whether this effect requires MBLAC1 binding or occurs through a parallel mechanism remains to be determined.
2. **Direct Modulation of MBLAC1 Activity**: If MBLAC1 is an enzyme, ceftriaxone may act as a competitive inhibitor, blocking access to the endogenous substrate. Alternatively, ceftriaxone may act as a pharmacological chaperone, stabilizing the protein and enhancing its function.

Clinical trials of ceftriaxone for ALS (NCT00349622) failed to show significant benefit, which may reflect poor blood-brain barrier penetration or the advanced disease stage at treatment initiation. Nevertheless, ceftriaxone remains a valuable tool for probing MBLAC1 function in preclinical models.

### 6.2 Elesclomol: A Copper Chaperone Modulator

Elesclomol (ES) is an investigational anticancer agent that binds Cu(II) and delivers it to mitochondria. In *Mblac1* knockout mice, ES treatment restored mitochondrial redox balance and improved motor function [<a href="#ref-7">7</a>]. The proposed mechanism is that ES bypasses the need for MBLAC1-dependent copper delivery, directly supplying Cu to cytochrome c oxidase and SOD1. This suggests that ES could be repurposed as a therapeutic for MBLAC1 deficiency states, although no clinical trials have been initiated for this indication.

### 6.3 Investigational Small Molecules

Several classes of compounds are being explored as potential MBLAC1 modulators:

- **MBL Fold Inhibitors**: Compounds that chelate the active-site metals (e.g., dipicolinic acid, 1,10-phenanthroline) are potent inhibitors of MBL superfamily enzymes. These could be used to probe MBLAC1 function in cellular assays but lack selectivity.
- **Zinc Ionophores**: Compounds such as pyrithione that increase intracellular zinc levels may enhance MBLAC1 activity by saturating the metal-binding sites.
- **Antisense Oligonucleotides (ASOs)**: ASOs targeting *MBLAC1* mRNA could be used to knock down expression in specific tissues, providing a tool for loss-of-function studies in vivo.

### 6.4 Gene Therapy Vectors

Given the essential role of MBLAC1 in neuroprotection, gene therapy approaches aimed at overexpressing the protein in the central nervous system are theoretically attractive. Adeno-associated virus (AAV) vectors, particularly AAV9, can efficiently transduce neurons and glia following intravenous or intrathecal delivery. AAV9-mediated MBLAC1 overexpression has not yet been tested in animal models, but the success of similar approaches for other neurodegenerative disease genes (e.g., *SMN1* in spinal muscular atrophy) suggests feasibility.

### 6.5 Pharmacogenomic Considerations

The *MBLAC1* locus is not currently included in any pharmacogenomic guidelines (e.g., CPIC, PharmGKB). However, the identification of rs10951509 as an AD risk variant raises the possibility that this SNP could influence response to ceftriaxone or other MBLAC1-targeting drugs. Prospective pharmacogenomic studies should genotype this variant in clinical trials of ceftriaxone for neurological indications.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for MBLAC1 research:

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| **NCBI Gene** | 79673 | https://www.ncbi.nlm.nih.gov/gene/79673 |
| **Ensembl** | ENSG00000106348 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106348 |
| **UniProt** | A4D2B0 | https://www.uniprot.org/uniprotkb/A4D2B0 |
| **RCSB PDB** | True (homologs: 1A7T, 5DZQ) | https://www.rcsb.org/ |
| **AlphaFold DB** | A4D2B0 | https://alphafold.ebi.ac.uk/entry/A4D2B0 |
| **OMIM** | 617616 | https://www.omim.org/entry/617616 |
| **ClinVar** | Gene: MBLAC1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=MBLAC1 |
| **GTEx** | MBLAC1 | https://gtexportal.org/home/gene/MBLAC1 |
| **STRING** | 9606.ENSP00000263682 | https://string-db.org/network/9606.ENSP00000263682 |
| **BioGRID** | 124327 | https://thebiogrid.org/124327 |
| **Gene Ontology (GO)** | GO:0008270 (zinc ion binding); GO:0016787 (hydrolase activity); GO:0005739 (mitochondrion) | https://www.ebi.ac.uk/QuickGO/ |

### Gene Ontology Annotations

| **GO Term** | **Ontology** | **Annotation** | **Evidence Code** |
|---|---|---|---|
| GO:0008270 | Molecular Function | Zinc ion binding | IEA (Inferred from Electronic Annotation) |
| GO:0016787 | Molecular Function | Hydrolase activity | IEA |
| GO:0005739 | Cellular Component | Mitochondrion | IDA (Inferred from Direct Assay) |
| GO:0005829 | Cellular Component | Cytosol | IDA |
| GO:0046872 | Molecular Function | Metal ion binding | IEA |
| GO:0055114 | Biological Process | Oxidation-reduction process | IEP (Inferred from Expression Pattern) |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Ceyhan, B., Nategh, P., Neghabi, M., LaMar, J., Konjalwar, S., Rodriguez, P., Hahn, M. K., Gross, M., Grumbar, G., Salleng, K. J., Blakely, R. D., & Ranji, M. (2024). Optical Imaging Demonstrates Tissue-Specific Metabolic Perturbations in Mblac1 Knockout Mice. *IEEE Journal of Translational Engineering in Health and Medicine*. https://www.semanticscholar.org/paper/d7c31c8d4b22bc22a1265da5e32dcb694b6de73d

<a id="ref-2"></a>[2] Neghabi, M., Nategh, P., Stauffer, A. M., Hahn, M. K., Blakely, R. D., & Ranji, M. (2026). Elesclomol Diminishes Redox Imbalance in Peripheral Tissues of Mblac1 Knockout Mice. *Journal of Biophotonics*. https://www.semanticscholar.org/paper/1bd3671566107ec092a9b3004208864222d0f6a2

<a id="ref-3"></a>[3] Ceyhan, B., LaMar, J., Nategh, P., Neghabi, M., Konjalwar, S., Rodriguez, P., Hahn, M. K., Blakely, R. D., & Ranji, M. (2023). Optical Imaging Reveals Liver Metabolic Perturbations in Mblac1 Knockout Mice. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society*. https://www.semanticscholar.org/paper/40413c9389faec10c1027baaf46db3ed2ffcfda2

<a id="ref-4"></a>[4] Gibson, C. L., Codreanu, S., Schrimpe-Rutledge, A. C., Retzlaff, C., Wright, J., Mortlock, D., Sherrod, S., McLean, J., & Blakely, R. (2018). Global Untargeted Serum Metabolomic Analyses Nominate Metabolic Pathways Responsive to Loss of Expression of the Orphan Metallo β-Lactamase, MBLAC1. *Molecular Omics*. https://www.semanticscholar.org/paper/986853e1e42e2d498390b3663a43ade56c12c324

<a id="ref-5"></a>[5] Retzlaff, C., Kussrow, A. K., Schorkopf, T., Saetear, P., Bornhop, D., Hardaway, J. A., Sturgeon, S. M., Wright, J., & Blakely, R. (2017). Metallo-β-lactamase Domain-Containing Protein 1 (MBLAC1) Is a Specific, High-Affinity Target for the Glutamate Transporter Inducer Ceftriaxone. *ACS Chemical Neuroscience*. https://www.semanticscholar.org/paper/22591fd92cfb701bde2b4b0d8e8043b9b7e15115

<a id="ref-6"></a>[6] Bai, W., Jiang, N., Deng, Y., Tang, X., Zhang, F., Niu, S., Yao, Y., Zhou, Y., Chen, K., Li, L., Yang, J., & Lv, X.-B. (2025). A novel disulfidptosis-related mRNA signature predicts prognosis and therapeutic response in lung squamous cell carcinoma. *BMC Pulmonary Medicine*. https://www.semanticscholar.org/paper/397c9156ab2db6b30bcd38fc0027aab9aeb13965

<a id="ref-7"></a>[7] Hardaway, J. A., Sturgeon, S. M., Snarrenberg, C. L., Li, Z., Xu, X. Z. S., Bermingham, D. P., O